MARLBOROUGH, Mass.,
Jan. 5, 2015 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced that the Company's President and
Chief Executive Officer, Dr. Geert
Cauwenbergh, will present at the 7th Annual
Biotech Showcase™ 2015 on Monday, January
12, 2015 at 9:30 a.m.
PST. Dr. Cauwenbergh will provide an update on the
Company's Dermatology and Ophthalmology Franchises. He will also
discuss business development opportunities with RXi's broad
delivery technology platform as well as the Company's robust
intellectual property portfolio.
The presentation will be webcast and available on the
"Investors" section of the Company's website,
www.rxipharma.com.
To schedule a meeting with RXi Pharmaceuticals' management team
at this conference, contact Investor Relations at
ir@rxipharma.com.
About the Biotech Showcase
Co-produced by Demy-Colton Life Science Advisors and EBD Group,
Biotech Showcase is an investor and partnering conference devoted
to providing private and public biotechnology and life sciences
companies an opportunity to present to, and meet with, investors
and pharmaceutical executives during the course of one of the
industry's largest annual healthcare investor conferences.
Investors and biopharmaceutical executives from around the world
gather in San Francisco during
this critical week which is widely viewed as setting the tone for
the coming year. Now in its seventh year, Biotech Showcase is
expected to attract upwards of 1,700 attendees. This
conference will take place January 12-14,
2015 at the Parc 55 Wyndham San Francisco Union Square
Hotel, California.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use
RNA interference, or "RNAi," have great promise because of
their ability to down-regulate the expression of specific genes
that may be over-expressed in disease conditions. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, a self-delivering RNAi compound (sd-rxRNA), entered into
human clinical trials in June 2012
and is currently being evaluated in Phase 2 clinical trials to
reduce the formation of dermal fibrosis (e.g., hypertrophic scars
and keloids). RXI-109 is designed to reduce the expression of
connective tissue growth factor (CTGF), a critical regulator of
biological pathways involved in fibrosis, including scar formation
in the skin. RXi's sd‑rxRNA oligonucleotides are designed for
therapeutic use and have drug-like properties, such as high
potency, target specificity, serum stability, reduced immune
response activation, and efficient cellular uptake. These hybrid
oligonucleotide molecules combine the beneficial properties of
conventional RNAi and antisense technologies. This allows
sd‑rxRNAs to achieve efficient cellular uptake and potent,
long-lasting intracellular activity. For more information, please
visit www.rxipharma.com.
Forward-Looking Statements
This communication contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products, technologies and
partnerships. Forward-looking statements about expectations and
development plans of RXi's products and partnerships involve
significant risks and uncertainties such as: the risk that we
may not be able to successfully develop our candidates, or that
development of RNAi-based therapeutics may be delayed or not
proceed as planned, or that we may not develop any RNAi-based
products; risks that the development process for our product
candidates may be delayed, risks related to the development and
commercialization of products by our competitors, the risk related
to our ability to control the timing and terms of collaborations
with third parties, the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products. Actual results may differ from those
contemplated by these forward-looking statements. RXi does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this communication.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-7th-annual-biotech-showcase-300015370.html
SOURCE RXi Pharmaceuticals Corporation